[Featured Stock] Myeongmun Pharmaceutical Shows Presence in 130 Trillion Won Obesity Treatment Market... Appetite Suppressants 3 Re-evaluated Highlighted↑

Myeongmun Pharmaceutical is showing strong performance. This is interpreted as being influenced by recent news highlighting the growth potential of the obesity treatment market and the attention on Myeongmun Pharmaceutical's appetite suppressant products.

As of 10:23 AM on the 1st, Myeongmun Pharmaceutical is trading at 2,590 KRW, up 9.05% compared to the previous day.

According to industry sources, Myeongmun Pharmaceutical recently announced that it is conducting bioequivalence tests (hereafter referred to as bioequivalence tests) for three appetite suppressant products: 'Lenocin (Diethylpropion Hydrochloride)', 'Redipen (Phentermine Hydrochloride)', and 'Pentacin Tablets (Phendimetrazine Tartrate)'.

Myeongmun Pharmaceutical has a very positive outlook on the results of these bioequivalence tests. If the results are favorable, the company plans to reflect the findings in the approval documentation in the second half of 2024.

Currently, in the domestic obesity treatment market, Novo Nordisk's GLP-1 analog 'Saxenda' (non-narcotic) is dominating. Unlike Saxenda, which is administered once daily, the same company's 'Wegovy', administered once weekly, was also approved by the Ministry of Food and Drug Safety in April.

According to the World Health Organization (WHO), the global obese population is expected to reach about 24% of the world’s total population by 2035. Consequently, the global obesity treatment market forecast for 2030 has been revised upward from the previous $30 billion to $50 billion range to $100 billion (approximately 132.35 trillion KRW).

This content was produced with the assistance of AI translation services.